|
IDXG Interpace Biosciences Inc 1054102 |
| Income Statement |
|
Revenue
|
form10-q
|
12,295,000 |
|
Net Income
|
form10-q
|
1,280,000 |
|
Profit Margin
|
|
10.41% |
| Balance Sheet |
|
Current Assets
|
11,110,000 |
|
Assets
|
14,039,000 |
|
Current Liabilities
|
18,769,000 |
|
Liabilities
|
71,721,000 |
|
Equity
|
-57,682,000 |
|
Shares Out
|
4,056,000 |
| Cash Flow Statement |
|
Operating Cash Flow
|
3,462,000 |
|
Investing Cash Flow
|
-747,000 |
| Market Analysis |
Market Cap
|
6,899,066 |
|
Price
|
1.19 |
|
BVPS
|
2.00 |
|
PB
|
0.58 |
|
EPS
|
-8.18 |
|
PS
|
0.14 |
|
FCF
|
2,715,000 |
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view IDXG documents filed with the SEC.
IDXG Filings
Clear
